



FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, Ronald Trahan Associates Inc., (508) 359-4005, x108

VasoGenix Pharmaceuticals to present at Medtech Insight and Windhover Information's *In3 Medical Device Summit*, June 21-23, 2006, San Francisco

LENEXA, Kan., May 10, 2006 — VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that it will be presenting on Thursday at 10:40 A.M. PT at Medtech Insight and Windhover Information's *In3 Medical Device Summit*, June 21-23, 2006, at The Palace Hotel in San Francisco.

Today, many different drugs must be used to treat angina, heart attack and heart failure, collectively known as *Acute Coronary Syndromes (ACS)*. Tomorrow, there might be *one* drug that's effective against all these conditions—'CGRP' (Calcitonin Gene Related Peptide), what VasoGenix Pharmaceuticals believes is "the perfect heart drug" to treat ACS, the greatest single cause of death and medical expenses in the U.S.

"The body's natural response to a heart attack is to release CGRP to facilitate three crucial life-sustaining actions. The first is to dilate local vasculature to increase local blood flow and increase hemodynamic proficiency," explained Lee Southard, Ph.D., CEO of VasoGenix Pharmaceuticals. "The second is to protect heart muscle cells from the damaging effects caused by lack of oxygen (ischemia). And the third is to modulate the immune system in a way that reduces the inflammatory response. All these actions are meant to minimize heart muscle damage and subsequent scar tissue formation, while promoting the healing process. Thus, CGRP appears to be the perfect heart drug. But the peripheral nerves around the heart that store CGRP can release only a limited amount, which is insufficient to provide the necessary response. Within three years, we could have a completed proof-of-concept trial and first exit opportunity for VasoGenix investors—and there is no better venue at which to meet investors than at a Medtech Insight conference."

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. The *In3 Medical Device Summit* (www.meddevicesummit.com) is Medtech Insight's 21st investment and partnering event to date.

Vasogenix Pharmaceuticals is a privately held, emerging biopharmaceutical company focused on developing cardiovascular drugs. The Company is focused initially on positioning 'CGRP' (*Calcitonin Gene Related Peptide*) as a front-line treatment for Heart Failure.

Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by the use of words such as, "expects," "plans," "estimates," "projects," "promises," "intends," "believes," and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, to identify strategic partners or, if identified, the inability to enter into an acceptable agreement with such strategic partners and successfully concluding the development and regulatory processes. All forward-looking statements in this press release are made as of today, based upon information known to management as of the date hereof. VasoGenix assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.

#####